WO2004011001A1 - 水性液剤および光安定化された水性液剤 - Google Patents
水性液剤および光安定化された水性液剤 Download PDFInfo
- Publication number
- WO2004011001A1 WO2004011001A1 PCT/JP2003/009713 JP0309713W WO2004011001A1 WO 2004011001 A1 WO2004011001 A1 WO 2004011001A1 JP 0309713 W JP0309713 W JP 0309713W WO 2004011001 A1 WO2004011001 A1 WO 2004011001A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous liquid
- piperidino
- methoxy
- pyridyl
- chloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to (+)-(S) 1- [4-([4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butyric acid or a pharmaceutically acceptable acid addition salt thereof and a water-soluble compound. And an aqueous solution containing a metal chloride. Further, the present invention is characterized in that a water-soluble metal chloride is blended, and (+)-(S) -141 [4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidino] The present invention also relates to a photostable method for butyric acid or a pharmaceutically acceptable acid addition salt thereof.
- (+) 1 (S) 1 4— [4-[(4-chlorophenyl) (2-pyridinole) methoxy] piperidino] butyric acid and its pharmacologically acceptable acid addition salts have antihistamine effects. Has anti-allergic effects. Furthermore, it has the feature that secondary effects such as stimulation or suppression of the central nervous system often seen with conventional antihistamines are minimized, and it is used as an effective drug for treating humans and animals. (JP-B 5-33953, JP-A 2000-1987 84).
- (+) 1 (S) 4-[(4-[(4-chlorophenyl) (2-pyridinole) methoxy] piperidino] butyrate monobenzenesulfonate (generic name: bepotastine besylate) Tablets containing it have already been listed as a therapeutic agent for allergic rhinitis and pruritus associated with skin diseases.
- (+) — (S) -4 No stabilization of 1- [4-[(4-phenylenole) (2-pyridinole) methoxy] piperidino] butyric acid and its pharmacologically acceptable acid addition salts was observed.
- a general stabilization method a method of coexisting with an antioxidant such as BHT is known (JP-A-7-304670). Disclosure of the invention
- the present invention relates to stabilized (+)-(S) 1- [4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butyric acid or a pharmaceutically acceptable acid addition thereof. It is to provide an aqueous solution containing a salt.
- Another object of the present invention is to provide (+)-(S) 1-[[4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butyric acid or its pharmacologically acceptable acid addition in an aqueous solution.
- An object of the present invention is to provide a method for stabilizing light of a salt.
- (+) 1 (S) 1 4 1 [4 1 [(4 1 phenyl) (2-pyridinole) [Toxi] [piperidino] butyric acid or its pharmacologically acceptable acid addition salt has a lower limit of 0.1 lw / v% and an upper limit of 2.0 w / v%.
- the present invention relates to a method for stabilizing butyric acid.
- (+) 1- (S) -4-1 [4-((4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butyric acid.
- hydrohalides such as hydrochloride and hydrobromide
- inorganic acid salts such as sulfate, nitrate and phosphate
- Organic acid salts such as sulfonic acid salt, ethanesulfonic acid salt, benzenesulfonic acid salt, p-toluenesulfonic acid salt, cyclohexylsulfamic acid salt and 4-aminosalicylic acid salt are exemplified
- the content of is, as a monobenzenesulfonate, usually a lower limit of about 0.1 lw / v%, preferably about 0.3 wZv%, more preferably about 0.5 wZv%, an upper limit of about 2.0 w / v%, It is preferably about 1.5 w / v%, and the amount is appropriately reduced according to the purpose of use and the degree of the symptom.
- preferred water-soluble metal chlorides include alkali metal chlorides such as sodium chloride and potassium chloride, and alkaline earth metal chlorides such as calcium chloride. Or a combination of two or more. Particularly preferred is sodium chloride.
- the content of the water-soluble metal chloride is usually a lower limit of about 0.15 w / v%, an upper limit of about 1.5 wZ V%, and preferably a lower limit of 0.2 w / V%. Level, upper limit about 1.2wZv%.
- sodium chloride about 0.15 w / v%, about 0.2 w / v%, about 0.3 wZ v ° /.
- potassium chloride about 0.15 w / v% about 0.2 wZv%, about 0.3 w / v% or more, about 1.0 w / v%, about 0.9 wZv%, about 0.8 w / v% or less.
- calcium chloride it is about 0.2 w / v%, about 0.3 wZv% or more, about 1.5 w, v%, about 1.2 w / v% or less as a dihydrate.
- the concentration of these water-soluble metal chlorides may be adjusted in consideration of the amount of other isotonic agents, such as boric acid, which do not affect stabilization in the above concentration range. It is preferable to determine the value appropriately in the range of about 23 OmO sm to about 35 OmO sm. T / JP2003 / 009713
- additives such as a buffer, a preservative, a chelating agent, and a fragrance, which are generally used, may be appropriately added to the aqueous liquid preparation of the present invention.
- the buffer examples include a phosphate buffer, a borate buffer, a citrate buffer, a tartrate buffer, an acetate buffer, an amino acid and the like.
- Preservatives if example embodiment, chloride Benzaruko - ⁇ arm, quaternary en Moniumu salts such as chlorhexidine to Darukon acid chlorine, Paraokishi benzoate, Paraokishi benzoate Esuteru such as Paraokishi propyl benzoate, sorbic acid Contact Yopi And salts thereof.
- the chelating agent include sodium edetate and citric acid.
- fragrances include menthol, borneol, camphor, and eucalyptus oil.
- the ⁇ of the aqueous liquid preparation of the present invention is adjusted to about 4, 5, 6 or more and about 8.5, 8 or less.
- the aqueous liquid preparation of the present invention may appropriately contain other same or different kinds of pharmaceutically active ingredients as long as the object of the present invention is not adversely affected.
- aqueous liquid preparation of the present invention examples include eye drops, nasal drops, and ear drops.
- nasal drops When the aqueous liquid preparation of the present invention is used as nasal drops, it may be used as a spray.
- the aqueous liquid preparation of the present invention can be produced by a method known per se, for example, a liquid preparation or an eye drop described in the Japanese Pharmacopoeia 14th Edition, General Rules for Preparations.
- the aqueous liquid preparation of the present invention can be used for warm-blooded animals (for example, humans, rats, mice, rabbits, rabbits, pigs, dogs, cats, etc.).
- the aqueous liquid preparation of the present invention When used as, for example, eye drops, it can be used for allergic conjunctivitis, catarrh in spring, hay fever and the like.
- the dosage is, for example, (+)-(S) 141- [4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butyrate-benzenesulfonate (bepotastine besylate) 1.
- the ophthalmic solution of the present invention containing O w / v% is to be instilled in an adult, 1-2 drops of the ophthalmic solution may be applied 3 to 6 times a day. The frequency can be increased or decreased as appropriate depending on the degree of symptoms.
- BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in more detail with reference to Experimental Examples and Examples, but the present invention is not limited thereto.
- Aqueous liquid preparations containing bepotastine besylate (formulations 1 to 6) shown in the following [Table 1] were prepared by a conventional method, and filled into glass ampules at 5 mL each.
- a xenon long-life full Edome one coater manufactured by Suga Test Instruments Co., Ltd. FAL- 2 5 AX- E c
- 2 0 OW 'h / m irradiation with corresponding light into two or more irradiation a total near-ultraviolet radiation energy (Irradiation time: 23 to 34 hours)
- Exposure was measured with a Quinine actinic light system as described in Pharmaceutical Manufacturing Guidelines 2001.
- Aqueous liquid preparations containing bepotastine besylate (Prescriptions 7 to 9) shown in the following [Table 2] were prepared by a conventional method, and operated in the same manner as in Experimental Example 1 to observe the appearance of each liquid preparation.
- Table 2 — — — — — — — — — — —
- Aqueous liquid preparations containing bepotastine besylate (Prescriptions 13 to 17) shown in Table 4 below were prepared by a conventional method, and operated in the same manner as in Experimental Example 1 to observe the appearance of each liquid preparation. Table 4
- Formula 13 is pale black-green
- Formula 14 is black-green
- a precipitate was observed in both cases. This result indicates that when glycerin is added, bepotastine besylate is colored black-green even at a low concentration.
- Formulation 15 (pH 4) turned blue and a precipitate was observed.
- Formulation 16 (pH 6.8) turned black-green and a precipitate was observed.
- Formula 17 (pH 8.5) turned yellow-brown, but no precipitation was observed.
- bebotastine besylate is very unstable at near neutral pH. It also shows that glycerin does not improve the photostability of vebotastine besylate in the pH range of 4 to 8.5.
- 3.3 wZv% of glucose or mannitol was added instead of the glycerin of Formulation 16, a blackish green color was observed, and a precipitate was observed.
- the above components are used to prepare an ophthalmic solution in a conventional manner.
- Bepotastine besinoleate 1.0 g Sodium dihydrogen phosphate 'dihydrate 0.1 g Sodium chloride 0.68 g Benzalkonium chloride 0.005 g Sodium hydroxide
- Sterile purified water Total volume 100 mL Use an ingredient with a pH of 6.8 or more to prepare eye drops by the usual method.
- Bepotastine besinolate 1.5 g Sodium acetate trihydrate 0.1 g Sodium chloride 0.6 g Benzalkonium chloride 0.005 g Sodium hydroxide
- Sterile purified water Total volume 100 mL Use an ingredient with pH 4.0 or higher to make eye drops according to the usual method
- Bepotastine besinoleate 1.5 g Epsilon aminocaproic acid 0.1 g Sodium chloride 0.6 g Benzalco chloride-pum 0.005 g Sodium hydroxide
- Example 6 Ophthalmic solution Bepotastine besylate 1.5 g Cuenoic acid 0.1 Sodium chloride 0.6 g Benzalcoium chloride 0.005 g Sodium hydroxide
- Sterile purified water Total volume 100 mL Use the components with pH 6.8 or higher to make eye drops by the usual method
- Sterile purified water Total volume 100 mL Use the components with pH 6.8 or higher to make eye drops by the usual method
- Sterile purified water Total volume 100 mL Use the components with pH 6.8 or higher to make eye drops by the usual method
- Bepotastine besinoleate 1.5 g Sodium dihydrogen phosphate dihydrate 0.1 g Sodium chloride 0.6 g Benzalco chloride-pum 0.005 g Sodium hydroxide
- Sterile purified water Total volume 100 mL Use an ingredient with a pH of 6.8 or more to prepare an ophthalmic solution in the usual manner (
- Bepotastine besinoleate 1.0 g Sodium dihydrogen phosphate 'dihydrate 0.1 g Shiridani sodium 0.68 g Benzalco Chloride -Pem 0.005 g
- the aqueous solution containing (+)-(S) 1- [4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof is soluble in water.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/500,354 US8784789B2 (en) | 2002-07-31 | 2003-07-30 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
EP03771445A EP1525884B1 (en) | 2002-07-31 | 2003-07-30 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
JP2004524320A JP3631748B2 (ja) | 2002-07-31 | 2003-07-30 | 水性液剤および光安定化された水性液剤 |
AU2003252746A AU2003252746A1 (en) | 2002-07-31 | 2003-07-30 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
AT03771445T ATE528003T1 (de) | 2002-07-31 | 2003-07-30 | Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen |
US13/599,212 US8883825B2 (en) | 2002-07-31 | 2012-08-30 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US14/314,678 US8877168B1 (en) | 2002-07-31 | 2014-06-25 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US14/511,393 US9849121B2 (en) | 2002-07-31 | 2014-10-10 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-223804 | 2002-07-31 | ||
JP2002223804 | 2002-07-31 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/500,354 A-371-Of-International US8784789B2 (en) | 2002-07-31 | 2003-07-30 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US13/599,212 Division US8883825B2 (en) | 2002-07-31 | 2012-08-30 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US14/314,678 Continuation US8877168B1 (en) | 2002-07-31 | 2014-06-25 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004011001A1 true WO2004011001A1 (ja) | 2004-02-05 |
Family
ID=31184981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/009713 WO2004011001A1 (ja) | 2002-07-31 | 2003-07-30 | 水性液剤および光安定化された水性液剤 |
Country Status (9)
Country | Link |
---|---|
US (3) | US8784789B2 (ja) |
EP (1) | EP1525884B1 (ja) |
JP (1) | JP3631748B2 (ja) |
KR (1) | KR101016595B1 (ja) |
CN (1) | CN1293880C (ja) |
AT (1) | ATE528003T1 (ja) |
AU (1) | AU2003252746A1 (ja) |
ES (1) | ES2371340T3 (ja) |
WO (1) | WO2004011001A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103260623A (zh) * | 2010-10-06 | 2013-08-21 | 伊斯塔制药公司 | 贝托斯汀组合物 |
JP2014501779A (ja) * | 2011-01-04 | 2014-01-23 | イスタ・ファーマシューティカルズ・インコーポレイテッド | ベポタスチン組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4739340B2 (ja) * | 2005-07-22 | 2011-08-03 | 田辺三菱製薬株式会社 | 口腔内速崩壊性錠 |
CN104119314B (zh) * | 2013-04-23 | 2018-01-12 | 重庆华邦制药有限公司 | 一种稳定的苯磺酸贝他斯汀晶体及其制备方法 |
CN106038480B (zh) * | 2015-04-16 | 2019-02-22 | 江苏恒瑞医药股份有限公司 | 一种光稳定的水性液体制剂 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07304670A (ja) | 1994-03-15 | 1995-11-21 | Senju Pharmaceut Co Ltd | プラノプロフェンの安定化方法および安定なプラノプロフェン水性液剤 |
WO1998029409A1 (fr) | 1996-12-26 | 1998-07-09 | Ube Industries, Ltd. | Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe |
JP2929274B2 (ja) | 1996-08-15 | 1999-08-03 | エーザイ株式会社 | 点眼液の光安定化方法 |
JPH11228404A (ja) | 1997-12-11 | 1999-08-24 | Senju Pharmaceut Co Ltd | 安定な水性点眼剤 |
WO2001002002A1 (en) | 1999-07-01 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Stabilized pharmaceutical composition in lyophilized form |
JP2001261553A (ja) | 2000-03-22 | 2001-09-26 | Tanabe Seiyaku Co Ltd | 経口投与製剤 |
EP1136084A1 (de) | 2000-03-18 | 2001-09-26 | Aventis Behring GmbH | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
WO2001080858A1 (fr) | 2000-04-24 | 2001-11-01 | Daiichi Pharmaceutical Co., Ltd. | Preparation liquide stable |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053628A (en) * | 1971-05-12 | 1977-10-11 | Fisons Limited | Composition |
US4929618A (en) | 1988-03-25 | 1990-05-29 | Ube Industries, Ltd. | Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same |
US5290774A (en) | 1989-08-03 | 1994-03-01 | Eisai Co., Ltd. | Photostabilizing method for ophthalmic solutions and the resulting ophthalmic solutions therefrom |
JPH0418015A (ja) * | 1990-05-10 | 1992-01-22 | Fujikawa Kk | 安定なフマル酸クレマスチン水溶液 |
TW230771B (ja) * | 1990-08-09 | 1994-09-21 | Sankyo Co | |
JP3225976B2 (ja) * | 1992-05-29 | 2001-11-05 | キヤノン株式会社 | カラー画像形成装置 |
CN1091597C (zh) | 1994-03-15 | 2002-10-02 | 千寿制药株式会社 | 稳定双吡苯丙酸的方法和稳定的双吡苯丙酸液体制剂 |
SE9401109D0 (sv) * | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
US5599534A (en) * | 1994-08-09 | 1997-02-04 | University Of Nebraska | Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use |
JP3107784B2 (ja) * | 1996-12-26 | 2000-11-13 | 宇部興産株式会社 | 光学活性ピペリジン誘導体の酸付加塩及びその製法 |
JP3361713B2 (ja) * | 1997-02-26 | 2003-01-07 | 大八化学工業株式会社 | トリブロモネオペンチルリン酸クロロアルキルエステルの製造方法 |
ES2302881T3 (es) * | 1997-07-29 | 2008-08-01 | Alcon Laboratories, Inc. | Composiciones oftalmicas que contienen polimeros de galactomanana y borato. |
US6174914B1 (en) | 1999-06-15 | 2001-01-16 | Alcon Laboratories, Inc. | Method of inhibiting cytokine release from human ocular cells |
US6369001B1 (en) * | 1999-08-11 | 2002-04-09 | Monsanto Technology, Llc | Microemulsion coformulation of a graminicide and a water-soluble herbicide |
ES2199873T3 (es) * | 1999-11-01 | 2004-03-01 | Alcon Inc. | Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma xantan. |
JP2001261563A (ja) | 2000-03-16 | 2001-09-26 | Cci Corp | マトリックスメタロプロテアーゼ産生抑制剤 |
UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
KR20030097892A (ko) * | 2001-05-25 | 2003-12-31 | 에스에스 세야쿠 가부시키 가이샤 | 의약 배합제 |
JP2011520963A (ja) | 2008-05-19 | 2011-07-21 | アルコン リサーチ, リミテッド | カルボキシビニルポリマーおよびポビドンポリマーを有する医薬組成物 |
-
2003
- 2003-07-30 AU AU2003252746A patent/AU2003252746A1/en not_active Abandoned
- 2003-07-30 US US10/500,354 patent/US8784789B2/en active Active
- 2003-07-30 WO PCT/JP2003/009713 patent/WO2004011001A1/ja active Application Filing
- 2003-07-30 ES ES03771445T patent/ES2371340T3/es not_active Expired - Lifetime
- 2003-07-30 KR KR1020047010338A patent/KR101016595B1/ko active IP Right Review Request
- 2003-07-30 JP JP2004524320A patent/JP3631748B2/ja not_active Expired - Lifetime
- 2003-07-30 CN CNB038019035A patent/CN1293880C/zh not_active Expired - Lifetime
- 2003-07-30 EP EP03771445A patent/EP1525884B1/en not_active Expired - Lifetime
- 2003-07-30 AT AT03771445T patent/ATE528003T1/de not_active IP Right Cessation
-
2012
- 2012-08-30 US US13/599,212 patent/US8883825B2/en not_active Expired - Lifetime
-
2014
- 2014-10-10 US US14/511,393 patent/US9849121B2/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07304670A (ja) | 1994-03-15 | 1995-11-21 | Senju Pharmaceut Co Ltd | プラノプロフェンの安定化方法および安定なプラノプロフェン水性液剤 |
JP2929274B2 (ja) | 1996-08-15 | 1999-08-03 | エーザイ株式会社 | 点眼液の光安定化方法 |
WO1998029409A1 (fr) | 1996-12-26 | 1998-07-09 | Ube Industries, Ltd. | Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe |
JPH11228404A (ja) | 1997-12-11 | 1999-08-24 | Senju Pharmaceut Co Ltd | 安定な水性点眼剤 |
WO2001002002A1 (en) | 1999-07-01 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Stabilized pharmaceutical composition in lyophilized form |
EP1136084A1 (de) | 2000-03-18 | 2001-09-26 | Aventis Behring GmbH | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
JP2001261553A (ja) | 2000-03-22 | 2001-09-26 | Tanabe Seiyaku Co Ltd | 経口投与製剤 |
WO2001080858A1 (fr) | 2000-04-24 | 2001-11-01 | Daiichi Pharmaceutical Co., Ltd. | Preparation liquide stable |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103260623A (zh) * | 2010-10-06 | 2013-08-21 | 伊斯塔制药公司 | 贝托斯汀组合物 |
JP2013539758A (ja) * | 2010-10-06 | 2013-10-28 | イスタ・ファーマシューティカルズ・インコーポレイテッド | ベポタスチン組成物 |
JP2014501779A (ja) * | 2011-01-04 | 2014-01-23 | イスタ・ファーマシューティカルズ・インコーポレイテッド | ベポタスチン組成物 |
US10736841B2 (en) | 2011-01-04 | 2020-08-11 | Bausch & Lomb Incorporated | Bepotastine compositions |
Also Published As
Publication number | Publication date |
---|---|
KR20050025137A (ko) | 2005-03-11 |
ATE528003T1 (de) | 2011-10-15 |
EP1525884A1 (en) | 2005-04-27 |
US20150031724A1 (en) | 2015-01-29 |
EP1525884B1 (en) | 2011-10-12 |
US8883825B2 (en) | 2014-11-11 |
KR101016595B1 (ko) | 2011-02-22 |
JP3631748B2 (ja) | 2005-03-23 |
US20120322825A1 (en) | 2012-12-20 |
CN1612734A (zh) | 2005-05-04 |
JPWO2004011001A1 (ja) | 2005-11-24 |
US9849121B2 (en) | 2017-12-26 |
CN1293880C (zh) | 2007-01-10 |
US8784789B2 (en) | 2014-07-22 |
US20050107429A1 (en) | 2005-05-19 |
AU2003252746A1 (en) | 2004-02-16 |
EP1525884A4 (en) | 2007-10-31 |
ES2371340T3 (es) | 2011-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11918573B2 (en) | Ophthalmic formulations of cetirizine and methods of use | |
US20100240624A1 (en) | Ophthalmic Formulations of Ketotifen and Methods of Use | |
CZ283693A3 (en) | Antiallergic preparations for use in ophthalmology and otorhinology | |
WO2010141834A1 (en) | Ophthalmic formulations of fluticasone and methods of use | |
CN101426502A (zh) | 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 | |
JP4106232B2 (ja) | 医薬組成物 | |
US9849121B2 (en) | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | |
JP4827385B2 (ja) | アズレン含有水性液剤 | |
JPH049339A (ja) | 抗アレルギー及び抗ヒスタミン組成物 | |
NO337768B1 (no) | Væskeformig, farmasøytisk preparat av piperazinderivater, og minst ett konserveringsmiddel av parahydroksybenzoatestere | |
US8877168B1 (en) | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | |
JP5252846B2 (ja) | 水性医薬組成物 | |
US20210299121A1 (en) | Cetirizine ophthalmic compositions | |
WO2002040028A1 (fr) | Gouttes pour les yeux en gel antibacterien | |
Murphy | Antihistamine toxicosis | |
JP2006169112A (ja) | オキサゾリジノン誘導体含有眼局所投与用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004524320 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003771445 Country of ref document: EP Ref document number: 1020047010338 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038019035 Country of ref document: CN Ref document number: 10500354 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003771445 Country of ref document: EP |